Literature DB >> 1336489

Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation.

G Orengo1, E Noviello, G Cimoli, G Pagnan, S Parodi, M Venturini, P Conte, F Schenone, G Conzi, P Russo.   

Abstract

Recombinant human tumor necrosis factor (rHuTNF) synergistically potentiates the cytotoxicity of the topoisomerase I inhibitor camptothecin, and the topoisomerase II inhibitors epidoxorubicin, etoposide, mitoxantrone, ellipticine, actinomycin D and 4'-(9-acridinylamino)methanesulfon-m-anisidide on A2780 human ovarian cancer cell line. Similar synergy was not observed with a combination of rHuTNF and cis-platinum or mitomycin C. When A2780 cells were incubated with rHuTNF simultaneously with camptothecin or mitoxantrone or VP16, increased numbers of DNA single-strand breaks were produced. rHuTNF alone did not induce DNA strand breakage. These data provide evidence that the enhancing effect of rHuTNF is closely related to the DNA damage mediated by topoisomerase-targeted drugs. These observations may have relevance for ovarian cancer treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1336489      PMCID: PMC5918720          DOI: 10.1111/j.1349-7006.1992.tb02735.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  19 in total

1.  Effect of recombinant human tumor necrosis factor on A2774 human ovarian cancer cell line: potentiation of mitoxantrone cytotoxicity.

Authors:  A Vigani; S Chiara; L Miglietta; L Repetto; P F Conte; G Cimoli; L Morelli; G Billi; S Parodi; P Russo
Journal:  Gynecol Oncol       Date:  1991-04       Impact factor: 5.482

Review 2.  Topoisomerase-targeting antitumor drugs.

Authors:  P D'Arpa; L F Liu
Journal:  Biochim Biophys Acta       Date:  1989-12-17

3.  Recombinant human tumor necrosis factor alone and with chemotherapeutic agents. Effect on nude mouse-supported human bladder cancer heterografts.

Authors:  A K Das; P J Walther; N J Buckley; S H Poulton
Journal:  Arch Surg       Date:  1989-01

4.  In vitro and in vivo anti-tumor activity of recombinant mouse tumor necrosis factor (TNF) in a mouse bladder tumor (MBT-2).

Authors:  R R Bahnson; T L Ratliff
Journal:  J Urol       Date:  1990-07       Impact factor: 7.450

5.  Effects of the DNA intercalators 4'-(9-acridinylamino)methanesulfon-m-anisidide and 2-methyl-9-hydroxyellipticinium on topoisomerase II mediated DNA strand cleavage and strand passage.

Authors:  Y Pommier; J K Minford; R E Schwartz; L A Zwelling; K W Kohn
Journal:  Biochemistry       Date:  1985-11-05       Impact factor: 3.162

6.  Isolation of intercalator-dependent protein-linked DNA strand cleavage activity from cell nuclei and identification as topoisomerase II.

Authors:  J Minford; Y Pommier; J Filipski; K W Kohn; D Kerrigan; M Mattern; S Michaels; R Schwartz; L A Zwelling
Journal:  Biochemistry       Date:  1986-01-14       Impact factor: 3.162

7.  Synergistic interactions between tumor necrosis factor and inhibitors of DNA topoisomerase I and II.

Authors:  Z Baloch; S Cohen; F D Coffman
Journal:  J Immunol       Date:  1990-11-01       Impact factor: 5.422

8.  Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation.

Authors:  T Utsugi; M R Mattern; C K Mirabelli; N Hanna
Journal:  Cancer Res       Date:  1990-05-01       Impact factor: 12.701

9.  Production of protein-associated DNA breaks by 8-methoxycaffeine, caffeine and 8-chlorocaffeine in isolated nuclei from L1210 cells: comparison with those produced by topoisomerase II inhibitors.

Authors:  P Russo; L Poggi; S Parodi; A M Pedrini; K W Kohn; Y Pommier
Journal:  Carcinogenesis       Date:  1991-10       Impact factor: 4.944

10.  Augmentation of antineoplastic effects by the combination of recombinant human tumor necrosis factor and mitoxantrone on primary culture of human ovarian cancer cells.

Authors:  G Cimoli; M Valenti; M Venturini; P Conte; P Russo
Journal:  Anticancer Res       Date:  1992 Sep-Oct       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.